Bemiparin
As of the edition of 20 October 2026, Bemiparin is an oligosaccharide: marketed; acts on F10.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Oligosaccharide
- Brand name
- Entervit
- Approvals on record
- 17 in 17 regions
- Holder of the most recent approval
- Gineladius, S.L.; 2 holders in all
- Registered trials
- 12, 4 stopped early
- Disease areas
- Heart and blood vessels; Cancer; Lungs and airways; Hormones; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| F10 | Coagulation factor X | P00742 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| Phase 3 | 5 | 2 | 0 | 2 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Rovi Pharmaceuticals | Lead sponsor of trials | 2005 to now |